Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02353715 · ClinicalTrials.gov registry record
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 38
- Enrollment target
NCT02353715 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 38 participants.
The verdict
NCT02353715 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This is a pilot exercise physiology and quality of life study of subjects receiving standard of care therapy for their prostate cancer using FDA-approved drugs per their labeling (abiraterone, enzalutamide, or sipuleucel-T). Subjects with progressive, asymptomatic or minimally symptomatic mCRPC scheduled to be treated with either enzalutamide or abiraterone acetate for ≥3 months or a course of sipuleucel-T will be allocated to one of the treatments arms, according to the treatment chosen by the treating physician.
Interventions
- DRUG Enzalutamide
- DRUG Sipuleucel-T
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-07-07 |
| Est. Completion | 2018-11-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02353715
The ClinicalTrials.gov registry entry for NCT02353715 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT02353715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02353715 about?
NCT02353715 is a clinical study titled "Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing". This is a pilot exercise physiology and quality of life study of subjects receiving standard of care therapy for their prostate cancer using FDA-approved drugs per their labeling (abiraterone, enzalutamide, or sipuleucel-T). Subjects with progressive, asymptomatic or minimally symptomatic mCRPC sche...
What is the current status of trial NCT02353715?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2015-07-07. Estimated completion is 2018-11-14.
What interventions are being tested in trial NCT02353715?
The interventions under investigation include: Enzalutamide (DRUG), Sipuleucel-T (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT02353715?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.